[Featured Stock] Cellumed Hits Upper Limit on News of Injectable Skin Graft Development
Bio and medical device company Cellumed is hitting the daily limit after news of developing an injectable skin graft product.
![[Featured Stock] Cellumed Hits Upper Limit on News of Injectable Skin Graft Development](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
As of 10:29 AM on the 30th, Cellumed is trading at 2,540 KRW, up 29.79% from the previous close.
On this day, Cellumed announced that it has completed the development of the new injectable skin graft product, 'Celluderm Gen,' and plans to begin production facility inspections and prototype development early next year.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Cellumed explained that 'Celluderm Gen' can be applied to simple procedures such as pain relief for degenerative arthritis and joint injections, allowing it to immediately contribute to sales upon commercialization, and its use in the cosmetic field is also on the rise.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
